Usingimproved selection techniques, we isolated four monoclonal antibodies with high affinity for human thyrotropin (Ka = 1.6 x 108to2.6 x lO10LJmoI).Weusedtwooftheseinan immunoradiometric assay (IRMA) that also incorporates a novel phase-separation technology (Sucrosep TSH IRMA, Boots-Ceiltech). This assay's very low detection limit for TSH (0.03-0.08 milli-int. unit/L) and wide working range (0-250 milli-int. unitlL) allow the differential diagnosis of hypothyroid, euthyroid, and hyperthyroid patients. We compare the utility of this IRMA with that of a RIA for patients with various thyroid disorders. As determined by IRMA, a normal concentration of TSH in serum excludes hyperthyroidism or hypothyroidism, whereas an undetectable serum TSH concentration (<0.08 milli-int. unit/L) accurately predicts an abnormality in thyroid gland function. The development of monoclonal antibodies was expected to remove these limitations, and one of us (E.C.R.) has previously described a highly specific monoclonal antibody to human TSH (4). Although this antibody had markedly improved specificity for TSH and was well-suited to immunofluorescence studies, its affinity was lower than that of the corresponding polyclonal antiserum, and it thus did not improve the performance of the resulting REA.
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In highly sensitive radioimmunoassays (RIA) for thyrotropin (TSH) in serum (e.g., 1, 2) polyclonal antisera and classical, competitive binding reactions are used.5 Timeconsuming to perform, they often require incubation for several days or sample extraction (3). Furthermore, their limited analytical sensitivity does not permit one to distinguish clearly between basal TSH values, for serum from euthyroid subjects, and the suppressed values seen in hyperthyroid patients.
The development of monoclonal antibodies was expected to remove these limitations, and one of us (E.C.R.) has previously described a highly specific monoclonal antibody to human TSH (4). Although this antibody had markedly improved specificity for TSH and was well-suited to immunofluorescence studies, its affinity was lower than that of the corresponding polyclonal antiserum, and it thus did not improve the performance of the resulting REA.
Fortunately, there have been further advances in monoclonal antibody technology and immunoassay technique.
Here we describe the production and selection of several monoclonal antibodies to TSH and their use in development of a highly sensitive two-site iminunoradiometric assay (IRMA) . We also compare the analytical and clinical performance of this IRrst& with that of a RIA for TSH that one of us previously developed (2) .
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Materials and Methods

Monoclonal Antibodies
Immunizations: Antibody specificity: We determined this, using the screening RIA described above but incubating the antibodies with 'I-labeled lutropin or '251-labeled follitropin. Only hybridoma cells secreting TSH-specific antibodies were investigated further.
Affinity estimates: We estimated relative binding aflinities for TSH by determining the binding of lmIlabeled TSH at various dilutions of each culture supernate, as described previously by one of us (8). Affinity constants (K,,) were estimated by the method of Adrion (9) from the antibody dilution giving 50% maximal binding of lmIlabeled TSH.
Antibody selection: We further evaluated the four highestaffinity TSH-specific monoclonal antibodies ("42," "258," and "286" from immunization procedure a and "323" from procedure b) for their potential use in a two-site mMA. After solution, were used to prepare solid-phase and radiolabeled antibody preparations. We coupled sodium sulfate fractions from each monoclonal antibody and from a sheep polyclonal anti-TSH serum (sAPu) to penodate-activated Sephacryl-S300 (Pharmacia) as previously described (10). After further purifying each fraction by gel-filtration on Sephadex G200 (Pharmacia) we also prepared radiolabeled monoclonal antibody with Nat25! (Amersham PLC, Amersham, U.K.), using a Chloramine-T procedure (11). We then sought complementary pairs by studying each possible combination of solidphase and radiolabeled antibody in a two-site ntzs.
Final purification of selected monoclonal antibodies:
Monoclonal antibody 323, selected for the mrs radiolabel, was produced in 100-L tissue culture in an air-lift fermenter (12) and purified from culture fluid by affinity chromatography on Protein A-Sepharose for a further hour. Free and solid-phasebound 'I-labeled monoclonal antibody fractions are separated by the sucrose-separation technique (7) and the radioactivity of the bound fraction is counted for 1 mm in a gamma-scintillation counter having a background count rate less than -60 counts/mm. In this study, we processed immunoassay data by using a five-parameter log-logistic curve fit (Boots-Celltech Diagnostics Ltd.) and an IBM-PC microcomputer.
Radioimmunoassays
The TSH RIA has been described previously (4). Briefly, in the procedure a rabbit polyclonal antiserum to human TSH is used and the total incubation time is seven days. This RIA has a formal detection limit of 0.3-0.5 milli-int. unit/L. Thyroxin (T4), triiodothyronine (T3), and T3-resin uptake assays were performed as previously described (13).
Patients
Serum was sampled from patients referred to the Thyroid Clinic of the Massachusetts General Hospital, Boston, MA. Unless stated, these patients were not taking thyroid medication and had no history of hypothalamic-pituitary disease. We performed routine thyroid-function tests on all specimens, including determinations of serum T3 and T4 and T3-resin uptake. We measured serum TSH by both RIA and
IRMA.
On the basis of clinical history, physical examination, and results of routine thyroid-function tests we classified 65 subjects as euthyroid. Of these, 23 were normal volunteers who also had normal TSH responses by RIA to thyroliberin stimulation (2). Twenty-six subjects had classical hyperthyroidism and 31 primary hypothyroidism.
We also studied 58 patients with primary hypothyroidism who were being treated with various dosages of L-thyrOxln (75-250 pg/d).
Fifteen subjects had autonomously functioning thyroid nodule, as defined by thyroid scans; three of these were classified as having "toxic" hyperfunctioning nodules, because values for either T4 or T3 in their serum were abnormally high. Twenty-one patients had characteristic multinodular goiters with normal values for T4, T3, and T3 resin uptake; none had clinical symptoms or signs of hyperthyroidism. 
Results
Characterization
Optimization
of nMA: Although antibody 42 had the higher estimated K,, value, we found that the TSH doseresponse curve of the flUIA was most sensitive when we used '25!-labeled antibody 323 and solid-phase antibody 42. We improved assay sensitivity by delaying the addition of the solid-phase reagent. As expected, we found the percentage of I-labeled monoclonal antibody bound in the m& to be related to its mass and we selected a concentration of 3.0 ng per tube for this reagent, a compromise between the requirements for TSH detection limit, working range, and acceptable count-rate. We selected solid-phase antibody concentrations in a similar series of experiments so as to ensure that this reagent was in true molar excess relative to TSH. sitivity (detection limit), defined as the smallest concentration of TSH that differs significantly from the zero standard (±2.5 SD), is 0.03-0.08 milli-int. unit/L. The range within which the assay has a within-assay CV <10% is 0.4-250 milli-int. units/L.
The specificity of the assay was determined in two ways (Table 1) : by assessing the cross reactivity of related hormones in the absence of TSH and by measuring interference by substances in the presence of TSH. We attribute the interference (<15%) by extremely high concentrations of human choriogonadotropin to low-affinity recognition of this hormone by the '251-labeled monoclonal antibody (no. 323). This interfering substance is not recognized by the solidphase antibody and does not cross react in the mrt.
Clinical performance of the m:
We compared results for TSH obtained with the IRMA with those by RIA ( Table 2) .
Eight of the 65 (12%) euthyroid subjects had undetectable TSH in the RIA, but TSH was detectable in all samples by the more-sensitive Hyperthyroid patients had undetectable TSH values by both RIA (<0.5 milli-int. unit/L) and IRMA (<0.08 milli-int. unitlL) in both basal samples and samples collected after thyroliberin injection.
The wider working range of the IRMA allowed us to assay all but one of the hypothyroid patients' sera without dilution, whereas all required dilution before analysis by RIA. TSH results for hypothyroid samples by the two methods correlated well (r = 0.88, P <0.001). In hypothyroid patients treated with L- thyroxin (75 to 250 g daily) 
Discussion
Until recently, the clinical utility of serum TSH determinations has generally been limited to that of an ancillary test in the confirmation of hypothyroid status after a primary finding of low thyroid-hormone concentrations in serum. Because of this limited analytical sensitivity, TSH RIA has not been helpful in the diagnosis of hyperthyroidism because the lower limit of the normal range for TSH is undefined.
Our previous isolation of a specific anti-TSH monoclonal antibody (4) failed to improve assay sensitivity significantly. We attributed this to the antibody's relatively low affinity for TSH (K,, = 4.0 x i0 LImol) and to certain deficiencies in the techniques then available for monoclonal antibody selection and immunoassay.
In this study, we demonstrate that it is possible to improve TSH measurement substantially by using monoclenal antibodies with affinities that are equal to or even lower than those found in many polyclonal antisera, if certain improvements in antibody selection and immunoassay design are used. For example, our use of antibody-dilution curves for '251-hormone preparations allowed us to select high-affinity antibodies at a very early stage after cell fusion.
The assay described involves a novel separation technique (Sucrosep) to achieve the full dose-response potential of the two-site IRMA. This technique provides very efficient washing of the solid-phase and results in excellent separation of bound and free radioactive fractions without centrifugation. After two washes, fewer than 50 counts per minute (from a total >50 000) of 'I-radiolabeled antibody are associated with the solid-phase in the absence of TSH: count misclassification rate of <0.1%. The resulting assay (Figure 1) is characterized by high sensitivity, excellent within-batch precision, and a working range that covers the entire pathophysiological range for TSH, a working range that obviates diluting sera from hypothyroid patients before assay in all but very extreme cases of increased TSH (>250 milli-int. units/L). This monoclonal-antibody-based IRMA also exhibits excellent specificity. In any two-site assay, we believe it is important to distinguish between the situation where related substances cross react (i.e., are recognized by both of the pair of monoclonal antibodies, giving rise to analytical overestimation) and those where substances interfere (i.e., are recognized by only a single member of the pair, giving rise to analytical underestimation).
Unlike many RIAs, this TSH IRMA shows no significant cross reaction with related hormones, including choriogonadotropin.
Although it does show slight interference by extremely high concentrations of hCG, we believe this is unlikely to be of diagnostic significance. In fact, this UtMA has recently allowed small, previously unrecognized physiological declines in TSH during early pregnancy to be identified (14) .
We, and others (15-19), have shown that these analytical advantages of the IRMA extend the clinical utility of TSH assay. In contrast to RIA, the increased analytical sensitivity of the m& allowed TSH to be detected in basal sera from all the euthyroid subjects studied; if a basal value for TSH in serum by IRMA falls within the normal range (0.5-5.0 millimt. units/L), it excludes a diagnosis of either hyperthyroidism or hypothyroidism. Similarly, an undetectable TSH by IRMA (but not by RIA) predicts an abnormality of thyroid function and is consistent with a number of disorders, including hyperthyroidism, hyperfunctioning thyroid nodule, multinodular goiter, and thyroid hormone suppression. In this instance, additional tests are required for a precise diagnosis. The IRMA'S ability to discriminate completely between hyperthyroid, euthyroid, and hypothyroid subjects confirms the suggestion (15, 16) that basal serum TSH determination by mi may suffice in the initial investigation of patients referred for thyroid evaluation. This allows thyroid testing strategies to be rationalized, and may decrease the total number of tests required (19).
